Lifitegrast for the Treatment of Dry Eye Disease
-
Published:2017-01
Issue:1
Volume:124
Page:53-60
-
ISSN:0161-6420
-
Container-title:Ophthalmology
-
language:en
-
Short-container-title:Ophthalmology
Author:
Holland Edward J.,
Luchs Jodi,
Karpecki Paul M.,
Nichols Kelly K.,
Jackson Mitchell A.,
Sall KennethORCID,
Tauber Joseph,
Roy Monica,
Raychaudhuri Aparna,
Shojaei Amir
Reference14 articles.
1. Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review;McDonald;Ocul Surf,2016
2. Dry eye as a mucosal autoimmune disease;Stern;Int Rev Immunol,2013
3. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007);Ocul Surf,2007
4. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease;Perez;Ocul Surf,2016
5. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye;Semba;Am J Ophthalmol,2012
Cited by
140 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献